Yaqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yaqi Wang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Huaiqiu Zhu
Department of Biomedical Engineering, College of Future Technology, and Center for Quantitative Biology, Peking University, Beijing, China
2 shared publications - Mo Li
Department of Biomedical Engineering, College of Future Technology, and Center for Quantitative Biology, and Center of Artificial Intelligence for Digital Life, Peking University, Beijing, China, 100871
2 shared publications - Qian Guo
Department of Biomedical Engineering, and Department of Big Data and Biomedical AI, College of Future Technology, and Center for Quantitative Biology, Peking University, Beijing 100871, China
2 shared publications - Xiaoqing Jiang
Department of Biomedical Engineering, and Department of Big Data and Biomedical AI, College of Future Technology, and Center for Quantitative Biology, Peking University, Beijing 100871, China
2 shared publications - Can Ni
State Key Laboratory for Turbulence and Complex Systems and Department of Biomedical Engineering
1 shared publication - Chunhui Wang
Department of Biomedical Engineering, College of Future Technology, and Center for Quantitative Biology, and Center of Artificial Intelligence for Digital Life, Peking University, Beijing, China, 100871
1 shared publication
Latest Publications
- Open Access
- 2 January 2024
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 13
IPEV: identification of prokaryotic and eukaryotic virus-derived sequences in virome using deep learning
Background: The virome obtained through virus-like particle enrichment contains a mixture of prokaryotic and eukaryotic virus-derived fragments. Accurate identification and classification of these elements are crucial to understanding their roles and functions in microbial communities. However, the rapid mutation rates of viral genomes pose challenges in developing high-performance tools for classification, potentially limiting downstream analyses. Findings: We present IPEV, a novel method to distinguish prokaryotic and eukaryotic viruses in viromes, with a 2-dimensional convolutional neural network combining trinucleotide pair relative distance and frequency. Cross-validation assessments of IPEV demonstrate its state-of-the-art precision, significantly improving the F1-score by approximately 22% on an independent test set compared to existing methods when query viruses share less than 30% sequence similarity with known viruses. Furthermore, IPEV outperforms other methods in accuracy on marine and gut virome samples based on annotations by sequence alignments. IPEV reduces runtime by at most 1,225 times compared to existing methods under the same computing configuration. We also utilized IPEV to analyze longitudinal samples and found that the gut virome exhibits a higher degree of temporal stability than previously observed in persistent personal viromes, providing novel insights into the resilience of the gut virome in individuals. Conclusions: IPEV is a high-performance, user-friendly tool that assists biologists in identifying and classifying prokaryotic and eukaryotic viruses within viromes. The tool is available at https://github.com/basehc/IPEV.
- 2 January 2024
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 13
Open AccessIPEV: identification of prokaryotic and eukaryotic virus-derived sequences in virome using deep learning
Background: The virome obtained through virus-like particle enrichment contains a mixture of prokaryotic and eukaryotic virus-derived fragments. Accurate identification and classification of these elements are crucial to understanding their roles and functions in microbial communities. However, the rapid mutation rates of viral genomes pose challenges in developing high-performance tools for classification, potentially limiting downstream analyses. Findings: We present IPEV, a novel method to distinguish prokaryotic and eukaryotic viruses in viromes, with a 2-dimensional convolutional neural network combining trinucleotide pair relative distance and frequency. Cross-validation assessments of IPEV demonstrate its state-of-the-art precision, significantly improving the F1-score by approximately 22% on an independent test set compared to existing methods when query viruses share less than 30% sequence similarity with known viruses. Furthermore, IPEV outperforms other methods in accuracy on marine and gut virome samples based on annotations by sequence alignments. IPEV reduces runtime by at most 1,225 times compared to existing methods under the same computing configuration. We also utilized IPEV to analyze longitudinal samples and found that the gut virome exhibits a higher degree of temporal stability than previously observed in persistent personal viromes, providing novel insights into the resilience of the gut virome in individuals. Conclusions: IPEV is a high-performance, user-friendly tool that assists biologists in identifying and classifying prokaryotic and eukaryotic viruses within viromes. The tool is available at https://github.com/basehc/IPEV.
- Open Access
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S182-S183
Abstract 1803: MEIS2 regulates BACE1 expression in Alzheimer’s disease models via transcriptional activation
- 13 April 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , S182-S183
Open AccessAbstract 1803: MEIS2 regulates BACE1 expression in Alzheimer’s disease models via transcriptional activation
- 5 January 2023
- Published by Elsevier in Environmental Research
- Vol. 220, 115238
Long-term effects of ambient PM2.5 constituents on metabolic syndrome in Chinese children and adolescents
- 5 January 2023
- Published by Elsevier in Environmental Research
- Vol. 220, 115238
Long-term effects of ambient PM2.5 constituents on metabolic syndrome in Chinese children and adolescents
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Gut Microbiota‐Related Effects of Tanhuo Decoction in Acute Ischemic Stroke
Acute ischemic stroke (AIS) is a major cause of acquired adult disability and death. Our previous studies proved the efficacy and effectiveness of Tanhuo decoction (THD) on AIS. However, the therapeutic mechanism remains unclear. We recruited 49 AIS patients and 30 healthy people to explore the effects of THD+basic treatment on the poststroke gut microbiota of AIS patients using 16S rRNA sequencing, in which 23 patients received basic treatment (control group) and 26 patients received THD+basic treatment (THD group). By comparing the data before and after treatments, we found the THD group acquired better outcome than the control group on both clinical outcome indices and the characteristics of gut microbiota. In addition to the mediation on short‐chain fatty acid‐ (SCFA‐) producing bacteria in two groups, treatment in the THD group significantly decreased the lipopolysaccharide‐ (LPS‐) producing bacteria to reduce LPS biosynthesis. Besides, the complexity of the cooccurrence of gut microbiota and the competition among LPS‐producing bacteria and opportunistic pathogenetic bacteria were enhanced in the THD group. Treatment in the THD group also exhibited the potential in decreasing genes on the biosynthesis of trimethylamine (TMA), the precursor of Trimethylamine N‐oxide (TMAO), and increasing genes on the degradation of TMA, especially increasing trimethylamine‐corrinoid protein Co‐methyltransferase (mttB) which catabolizes TMA to methane. These results hinted that THD+basic treatment might exert its efficacy by mediating the gut microbiota and microbial metabolites, including LPS and TMAO that aggravate the sterile inflammation and platelet aggregation. Moreover, the well‐fitting regression model results in predicting the clinical outcome with the alteration of gut microbiota proved gut microbiota as a potential indicator of AIS and provided evidence of the communication between the gut and brain of AIS patients.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessGut Microbiota‐Related Effects of Tanhuo Decoction in Acute Ischemic Stroke
Acute ischemic stroke (AIS) is a major cause of acquired adult disability and death. Our previous studies proved the efficacy and effectiveness of Tanhuo decoction (THD) on AIS. However, the therapeutic mechanism remains unclear. We recruited 49 AIS patients and 30 healthy people to explore the effects of THD+basic treatment on the poststroke gut microbiota of AIS patients using 16S rRNA sequencing, in which 23 patients received basic treatment (control group) and 26 patients received THD+basic treatment (THD group). By comparing the data before and after treatments, we found the THD group acquired better outcome than the control group on both clinical outcome indices and the characteristics of gut microbiota. In addition to the mediation on short‐chain fatty acid‐ (SCFA‐) producing bacteria in two groups, treatment in the THD group significantly decreased the lipopolysaccharide‐ (LPS‐) producing bacteria to reduce LPS biosynthesis. Besides, the complexity of the cooccurrence of gut microbiota and the competition among LPS‐producing bacteria and opportunistic pathogenetic bacteria were enhanced in the THD group. Treatment in the THD group also exhibited the potential in decreasing genes on the biosynthesis of trimethylamine (TMA), the precursor of Trimethylamine N‐oxide (TMAO), and increasing genes on the degradation of TMA, especially increasing trimethylamine‐corrinoid protein Co‐methyltransferase (mttB) which catabolizes TMA to methane. These results hinted that THD+basic treatment might exert its efficacy by mediating the gut microbiota and microbial metabolites, including LPS and TMAO that aggravate the sterile inflammation and platelet aggregation. Moreover, the well‐fitting regression model results in predicting the clinical outcome with the alteration of gut microbiota proved gut microbiota as a potential indicator of AIS and provided evidence of the communication between the gut and brain of AIS patients.